{"data":{"version":"methodology@2026-05-29","source":"BIO/QLS/Informa 2021 (Thomas et al.)","n":12728,"data_version":"2026-04-02","stages":["preclinical","phase_1","phase_2","phase_3","nda_bla"],"indications":["oncology_solid_tumor","oncology_hematologic","rare_disease","neurology","immunology","infectious_disease","cardiovascular","metabolic","respiratory","dermatology","ophthalmology"],"modalities":["small_molecule","monoclonal_antibody","bispecific","adc","cell_therapy","gene_therapy","peptide","other"],"biomarker_strategies":["none","enrichment","companion_dx"],"matrix_shape":{"indications":11,"modalities":8,"biomarker_strategies":3,"total_cells":264},"baseline":[{"indication":"oncology_solid_tumor","preclinical":0.04,"phase_1":0.62,"phase_2":0.24,"phase_3":0.4,"nda_bla":0.85,"overall_loa":0.0081},{"indication":"oncology_hematologic","preclinical":0.07,"phase_1":0.72,"phase_2":0.42,"phase_3":0.63,"nda_bla":0.9,"overall_loa":0.012},{"indication":"rare_disease","preclinical":0.08,"phase_1":0.56,"phase_2":0.38,"phase_3":0.64,"nda_bla":0.93,"overall_loa":0.0094},{"indication":"neurology","preclinical":0.04,"phase_1":0.46,"phase_2":0.2,"phase_3":0.47,"nda_bla":0.88,"overall_loa":0.0015},{"indication":"immunology","preclinical":0.06,"phase_1":0.49,"phase_2":0.3,"phase_3":0.58,"nda_bla":0.91,"overall_loa":0.0046},{"indication":"infectious_disease","preclinical":0.07,"phase_1":0.52,"phase_2":0.36,"phase_3":0.62,"nda_bla":0.92,"overall_loa":0.0074},{"indication":"cardiovascular","preclinical":0.05,"phase_1":0.48,"phase_2":0.28,"phase_3":0.55,"nda_bla":0.9,"overall_loa":0.0033},{"indication":"metabolic","preclinical":0.06,"phase_1":0.5,"phase_2":0.32,"phase_3":0.58,"nda_bla":0.91,"overall_loa":0.0051},{"indication":"respiratory","preclinical":0.05,"phase_1":0.47,"phase_2":0.26,"phase_3":0.54,"nda_bla":0.9,"overall_loa":0.0029},{"indication":"dermatology","preclinical":0.06,"phase_1":0.5,"phase_2":0.34,"phase_3":0.6,"nda_bla":0.91,"overall_loa":0.0056},{"indication":"ophthalmology","preclinical":0.06,"phase_1":0.5,"phase_2":0.3,"phase_3":0.58,"nda_bla":0.91,"overall_loa":0.0048}],"multipliers":[{"factor":"biomarker_enrichment","value":1.5,"applied_to":["phase_2","phase_3"],"source":"Parker et al. 2021 (Cancer Medicine); BIO 2021","source_estimand":"RR","applied_as":"OR"},{"factor":"biomarker_companion_dx","value":2,"applied_to":["phase_2","phase_3"],"source":"Parker et al. 2021 (Cancer Medicine)","source_estimand":"RR","applied_as":"OR"},{"factor":"genetic_validation","value":2.6,"applied_to":["phase_2","phase_3"],"source":"Minikel et al. 2024 Nature","source_estimand":"RR","applied_as":"OR"},{"factor":"orphan_designation","value":1.5,"applied_to":["phase_2","phase_3"],"source":"Mullard 2016 Nat. Rev. Drug Disc.","source_estimand":"RR","applied_as":"OR"},{"factor":"first_in_class","value":0.85,"applied_to":["phase_2","phase_3"],"source":"BIO/QLS 2021","source_estimand":"RR","applied_as":"OR"},{"factor":"car_t","value":1.73,"applied_to":["phase_1","phase_2"],"source":"Tufts NEWDIGS 2023","source_estimand":"RR","applied_as":"OR"},{"factor":"gene_therapy_orphan","value":1.41,"applied_to":["phase_1","phase_2"],"source":"Tufts NEWDIGS 2023","source_estimand":"RR","applied_as":"OR"}],"query_url":"/api/v1/benchmarks/pos/lookup","methodology_url":"/methodology/pos-calibration","public_page_url":"/benchmarks/pos","notes":["Baseline rows are small molecule × no biomarker. Modality- and biomarker-specific values are available via the POST /benchmarks/pos/lookup endpoint (in-product, via MCP, or via authenticated API call).","Multipliers are applied via log-odds (logit) transformation. See the methodology page for the full derivation.","Preclinical PoS is never adjusted by any multiplier; NDA/BLA approval rates reflect filing quality, not drug-specific clinical attributes."]}}